BeiGene licenses MAT2A cancer drug, matches with Ideaya’s combo plansnews2024-12-13T16:02:16+00:00December 13th, 2024|Endpoints News|
SABCS Roundup: BeiGene and Pfizer CDK4 inhibitors, ALX’s CD47news2024-12-13T15:57:04+00:00December 13th, 2024|Endpoints News|
Repare plans for Phase 3 endometrial cancer study, sidelining ovarian cancernews2024-12-13T15:56:49+00:00December 13th, 2024|Endpoints News|
iTeos drops adenosine A2A antagonist inupadenant to double down on TIGITnews2024-12-13T11:50:28+00:00December 13th, 2024|Endpoints News|
Editas to cut 65% of workforce, officially stops work on ex vivo sickle cell therapynews2024-12-12T22:09:20+00:00December 12th, 2024|Endpoints News|
FDA adcomm reviews safety signals from pediatric RSV trialsnews2024-12-12T20:56:22+00:00December 12th, 2024|Endpoints News|
Pfizer shares positive Phase 3 results in breast cancer subset news2024-12-12T13:15:38+00:00December 12th, 2024|Endpoints News|
Keros halts parts of Phase 2 PAH trial due to safety, stock tanks 70%news2024-12-12T12:15:54+00:00December 12th, 2024|Endpoints News|
Corcept’s ALS drug fails to improve function in Phase 2 studynews2024-12-12T11:44:49+00:00December 12th, 2024|Endpoints News|
Lilly to study obesity drugs in addiction, and is considering cognitive disordersnews2024-12-11T20:52:55+00:00December 11th, 2024|Endpoints News|
